奥曲肽结合生长抑素治疗粘连性肠梗阻患者的临床效果

Clinical effect of octreotide combined with somatostatin in the treatment of patients with adhesive intestinal obstruction

目的 探讨奥曲肽联合生长抑素治疗粘连性肠梗阻患者的临床效果。方法 选取2020年7月至2021年7月我院收治的60例粘连性肠梗阻患者为研究对象,以随机数字表法将其分为对照组和观察组,每组30例。对照组实施基础治疗,观察组在对照组基础上加用醋酸奥曲肽注射液与注射用生长抑素治疗。比较两组的治疗效果。结果 治疗后,两组的C-反应蛋白(CRP)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)及降钙素原(PCT)水平均显著低于治疗前,且观察组显著低于对照组(P<0.05)。治疗后,两组的内毒素、D-乳酸、二胺氧化酶(DAO)水平均低于治疗前,简明健康调查问卷(SF-36)评分均高于治疗前,且观察组优于对照组(P<0.05)。观察组的治疗总有效率显著高于对照组,不良反应总发生率显著低于对照组(P<0.05)。结论奥曲肽结合生长抑素治疗粘连性肠梗阻患者的效果较好,可调节炎症因子水平,促进肠黏膜屏障功能恢复,提升生活质量,值得推广及应用。

Objective To investigate the clinical effect of octreotide combined with somatostatin in the treatment of patients with adhesive intestinal obstruction.Methods A total of 60 patients with adhesive intestinal obstruction admitted in our hospital from July 2020 to July 2021 were selected as the research objects.The patients were divided into control group and observation group by random number table method,with 30 cases in each group.The control group was treated with basic treatment,and the observation group was treated with octreotide acetate injection and somatostatin for injection on the basis of the control group.The therapeutic effects of the two groups were compared.Results After treatment,the levels of C-reactive protein(CRP),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and procalcitonin(PCT)in the two groups were significantly lower than those before treatment,and those in the observation group were significantly lower than the control group(P<0.05).After treatment,the levels of endotoxin,D-lactic acid and diamine oxidase(DAO)in the two groups were lower than those before treatment,the Short Form-36 Health Survey(SF-36)score was higher than that before treatment,and those in the observation group were better than the control group(P<0.05).The total effective rate of treatment in the observation group was significantly higher than that in the control group,and the total incidence of adverse reactions was significantly lower than that in the control group(P<0.05).Conclusion Octreotide combined with somatostatin in the treatment of patients with adhesive intestinal obstruction has a better effect,it can regulate the levels of inflammatory factors,promote the recovery of intestinal mucosal barrier function and improve the quality of life,which is worthy of promotion and application.